Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact ir@baincapital.com.
Beijing, San Francisco and Boston, December 8, 2021 – Avistone Pharmaceuticals (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced it has received a strategic investment of more than $200 million led by Vivo Capital with participation from Bain Capital and Primavera Capital (collectively the “Investor...
Boston, MA, October 27, 2021 – Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment of up to $300 million from Bain Capital Life...
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III, Inc. (NASDAQ: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. today announced the closing of an oversubscribed $135 million Series C financing, led by Viking Global Investors, to support the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.The financing...
CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. today announced that it has closed a $260 million Series D financing led by D1 Capital Partners L.P. New investors HealthCor Investments LLC and Innovatus Capital Partners, LLC also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital,...
SAN DIEGO, June 9, 2021 /PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the closing of a $45 million financing tranche that brings the total Series D financing to more than $115 million. The financing includes participation by existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, as well as...
PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing. The round was co-led by Cormorant Asset Management and Fairmount Funds, and joined by Bain Capital Life Sciences,...
CAMBRIDGE, Mass., May 11, 2021 /PRNewswire/ -- Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the completion of a $135 million Series B financing. The round was led by Bain Capital Life Sciences with participation from sole founding investor, Deerfield Management, and additional new investors...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, and BCTG Acquisition Corp. (Nasdaq: BCTG), a special purpose acquisition company (SPAC) sponsored by Boxer Capital, today announced they have entered into a definitive merger agreement. Upon closing of the transaction, the...
CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced an up to $125 million non-dilutive financing transaction with NovaQuest and Bain Capital to fund the full Phase 3 development program for tavapadon in Parkinson’s disease, also known as the TEMPO...
2022 marks the 16th year of @Cycle4Survival. With over $312M raised for research and clinical trials led by MSK, th… https://t.co/6bZR5XJJVu
. @Danafarber @BrighamWomens Cancer Center's Skin Cancer Prevention Program is coming to a beach near you this summ… https://t.co/ZqeNQBcSSm
Be the first to know about all 2023 @Cycle4Survival events by signing up here. https://t.co/J2ympLVXkU
. @DanaFarber’s Irene Ghobrial, MD has been selected as the William Dameshek Prize winner. Learn more here.… https://t.co/iO2Y9c9Kar
On August 6 & 7, 2022, the @PanMass community will come together from all corners of the world with one mission: ra… https://t.co/C5oxDDaYOL
. @DanaFarber and @BrighamWomens have been designated as a Rare Disease Clinical Center for Pheochromocytoma & Para… https://t.co/XVMcD5gguX
We are excited to support @SumUp’s leadership team on product innovation, geographic expansion, and continued growt… https://t.co/RqKOC2upMB
We’re proud to partner with Nextalia SGR S.p.A. and @deltatre's CEO Andrea Marini to help the company continue to c… https://t.co/SKQff8oP4Q
Learn why one New Yorker has found a special connection with @TheJimmyFund and @RedSox in this blog.… https://t.co/L5RLt4aQhJ
. @DanaFarber has received a grant from the Richard K. Lubin Family Foundation to establish the Lubin Family Founda… https://t.co/5We7ZZMfLC